Shares of Omeros Co. (NASDAQ:OMER) traded up 5.7% during mid-day trading on Monday . The company traded as high as $26.62 and last traded at $26.46. 712,500 shares changed hands during trading, a decline of 29% from the average session volume of 998,051 shares. The stock had previously closed at $25.04.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, July 18th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Omeros in a report on Thursday, June 28th. ValuEngine downgraded shares of Omeros from a “buy” rating to a “hold” rating in a report on Wednesday, June 13th. Finally, Wedbush set a $20.00 price objective on shares of Omeros and gave the company a “hold” rating in a report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $27.56.

The company has a debt-to-equity ratio of -2.31, a quick ratio of 3.94 and a current ratio of 3.95. The firm has a market cap of $1.22 billion, a PE ratio of -32.23 and a beta of 3.84.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.04). The business had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.84 million. The firm’s quarterly revenue was down 90.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.33) earnings per share. analysts predict that Omeros Co. will post -2.48 EPS for the current fiscal year.

In other news, VP Marcia S. Kelbon sold 4,277 shares of the firm’s stock in a transaction dated Thursday, July 12th. The shares were sold at an average price of $21.48, for a total value of $91,869.96. Following the transaction, the vice president now directly owns 188,922 shares of the company’s stock, valued at $4,058,044.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Marcia S. Kelbon sold 40,723 shares of the firm’s stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $21.56, for a total transaction of $877,987.88. Following the completion of the transaction, the vice president now directly owns 219,645 shares in the company, valued at $4,735,546.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,529 shares of company stock worth $1,163,730. Insiders own 12.10% of the company’s stock.

Several large investors have recently bought and sold shares of OMER. Millennium Management LLC purchased a new position in shares of Omeros in the second quarter worth about $8,513,000. Capital Impact Advisors LLC purchased a new position in shares of Omeros in the second quarter worth about $1,749,000. Ingalls & Snyder LLC lifted its stake in shares of Omeros by 1.3% in the second quarter. Ingalls & Snyder LLC now owns 5,613,487 shares of the biopharmaceutical company’s stock worth $101,829,000 after buying an additional 70,625 shares in the last quarter. Alps Advisors Inc. purchased a new position in shares of Omeros in the second quarter worth about $1,271,000. Finally, Nisa Investment Advisors LLC purchased a new position in shares of Omeros in the second quarter worth about $1,099,000. 48.11% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile (NASDAQ:OMER)

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.